Why the study?
Do alpha-1 selective blockers provide a favorable alternative for treating hypertension in patients with lipid disorders or diabetes?
Do alpha-1 selective blockers provide a favorable alternative for treating hypertension in patients with lipid disorders or diabetes?
Alpha-blockers offer a favorable lipid profile and should be considered for hypertensive patients with lipid disorders, diabetes, or intolerance to standard therapies.
May support alpha-1 blockers in hypertensives with dyslipidemia; hypothesis-generating for outcomes versus standard agents.
Although beta-blockers and diuretics are presently the only medications shown to reduce morbidity and mortality in hypertensives in large clinical trials, these drugs have not exerted optimal expected benefits in reducing cardiac events. Alpha-1 selective blockers exhibit a favorable impact on lipids, particularly on HDL-cholesterol. Unlike beta-blockers, they do not increase triglycerides and they do not produce the increase in LDL-cholesterol observed with traditional doses of diuretics. Alpha-blockers should be considered in the treatment of hypertensives with lipid disorders or diabetes and in those who have contraindications, failure to respond or toxicity associated with diuretics and/or beta-blockade.
No takes yet. Share an insight, caveat, or question.
S. George Carruthers (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: